Literature DB >> 29264299

Multiple Dentigerous Cysts as a Rare Presentation of Maroteaux-Lamy Syndrome.

Ajaz Ahmad Shah1, Tajamul Ahmad Hakim1, Shahid Farooq1, Mubashir Younis1, Shamina Kosar1, Altaf Malik1, Latief Najar1.   

Abstract

Maroteaux-Lamy syndrome is one of the genetic disorders involving disturbances in mucopolysaccaride metabolism, due to deficiency of aryl sulfatase-B which leads to accumulation of dermatan sulfate in tissues and their excretion in urine. The diseases has several oral and dental manifestations, is first diagnosed on the basis of clinical findings. It is characterized by coarse facial features, normal intelligence, organomegaly, enlarged head, short neck, corneal clouding, enlarged tongue, and prominent metachromatic inclusions in leukocytes. Death is usually a result of either respiratory tract infection or cardiac disease, which is caused by the deposition of mucopolysaccharides. An 18-year-old with Maroteaux-Lamy syndrome is described in this article with multiple dentigerous cysts as the first presentation.

Entities:  

Keywords:  Genetic disorder; Maroteaux–Lamy syndrome; multiple dentigerous cysts

Year:  2017        PMID: 29264299      PMCID: PMC5717908          DOI: 10.4103/ams.ams_13_17

Source DB:  PubMed          Journal:  Ann Maxillofac Surg        ISSN: 2231-0746


INTRODUCTION

The mucopolysaccharidosis (MPSs) are a group of inherited disorders that results from the deficiency of one or more of the lysosomal enzymes required for glycosaminoglycans (GAG) catabolism.[23] MPSs Type VI or Maroteaux–Lamy syndrome, is a rare, autosomal recessively inherited GAG storage disease caused by deficiency of enzyme aryl sulfatase-B (ARSB). ARSB is required for the degradation of the GAG dermatan sulfate and chondroitin-4-sulfate. Aryl sulfate B deficiency causes intralysosomal accumulation and urinary excretion of large amounts of partially degraded dermatan sulfate.[4] Disease symptoms include growth retardation, coarse facial features, organomegaly, corneal clouding, multiple odontogenic cysts, and prominent metachromatic inclusions in peripheral blood leukocytes.[5] In contrast to most other MPSs, mental development in MPS Type VI is normal.[6] Diagnosis and management are often challenging because of the considerable variability in symptom presentation and rate of progression.

CASE REPORT

An 18-year-old male patient presented to the Department of Oral and Maxillofacial Surgery, Government Dental College and Hospital Srinagar, Jammu and Kashmir with a chief complaint of nasal obstruction on the right side for the past 3 months. Medical history of the patient revealed that he was suffering from severe obstructive sleep apnea from 1½ years of age, with a history of delayed milestones and cardiac abnormalities in childhood. Past dental history revealed gingival overgrowth that was operated at the age of 15 years and family history of consanguinous marriage of parents. Extraorally, he had frontal bossing, enlarged head, brachycephalic shape, euryproscopic face with convex profile, short neck, flattened nasal bridge, hypertrichosis, saddle nose, hypertelorism, and clouding of cornea. Intraorally, macroglossia, spacing of teeth and unerupted third molars. A panoramic radiograph and a computed tomography (CT) scan were taken and it indicated unerupted third molars with cyst formation in all the four quadrants [Figures 1-6]. Laboratory diagnosis revealed abnormal levels of GAG concentration in urine which was 224 mg GAG/g creatinine (normal range - 19.97–110.53). Enzyme assay revealed slightly low levels of ARSB that was 91.62 nmol/mg proton/h (normal value >121 nmol/mg proton/h) which is the pathognomonic sign of MPS Type VI.
Figure 1

Coarse facial features

Figure 6

Computed tomography scan showing maxillary cysts

Coarse facial features Broad nasal bridge Hypertelorism and corneal clouding Spacing Multiple dentigerous cysts Computed tomography scan showing maxillary cysts

Treatment plan

A cardiology and general physician checkup was done for the patient which did not reveal any major abnormality at present except slight cardiac anomaly in the form of ST segment elevation and right bundle branch block. MPS VI presents a significant anesthesia risk because of instability of the atlanto axial joint. In particular, induction of anesthesia can be difficult because of problems maintaining the airway. According to the American Heart Association guidelines, patient should receive bacterial endocarditis prophylaxis before dental or surgical procedure. After thorough evaluation patient was cleared for surgical intervention. A CT scan was done and the extentions of the cysts were noted. Right maxillary cyst measured 3.5 cm × 4 cm that pushed the right maxillary antrum medially and left maxillary cyst measured 2.9 cm × 3 cm. Right mandibular cyst measured 2.4 cm × 2 cm and left mandibular cyst measured 2 cm × 2.3 cm. Aspiration of the cysts revealed dirty white fluid with protein content of 7.1 g/dl. A treatment plan was decided and the patient was operated under local anesthesia. Marsupalization with opening into right antrum was done for right maxillary [Figure 7] cyst and marsupalization with secondary packing was done for left maxillary cyst [Figure 8]. Enuceation with primary closure was done for mandibular cysts [Figure 9] and the patient was treated with regular follow ups [Figure 10].
Figure 7

Marsupalization 1

Figure 8

Marsupalization 2

Figure 9

Enucleation of mandibular cyst

Figure 10

Postoperative orthopantomogram

Marsupalization 1 Marsupalization 2 Enucleation of mandibular cyst Postoperative orthopantomogram

DISCUSSION

The estimated birth prevalence is 1 in 320,000 live births in Europe. There is no current worldwide incidence rate and numbers may range according to country or specific ethnic populations studied. There are between 50 and 300 patients in the USA and approximately 1100 patients in the developed world with MPS VI.[7] Rapidly progressive forms usually present before 2 years of age with severe dysostosis multiplex and coarse facial features. Without proper treatment patients succumb before the second or third decade. A more slowly progressive (attenuated) form has been described with later onset, clinical symptoms in fewer systems, less pronounced dysostosis multiplex, and longer survival. The symptoms, onset and rate of progression of Maroteaux–Lamy syndrome vary greatly from one person to another. Review of literature shows different presentations of Maroteaux–Lamy syndrome [Table 1]. Some individuals may only have a few symptoms and others may have serious symptoms affecting several different organ systems simultaneously. Maroteaux–Lamy syndrome can potentially cause life-threatening complications. The variable nature of Maroteaux–Lamy syndrome means that most affected individuals will not have all the symptoms potentially associated with the disorder. Individuals with this disorder can differ from one another dramatically. In MPS VI, which is characterized by somatic features but not by mental retardation, the patients are able to lead a relatively normal life when compared to other types of the disease. MPS VI patients appear healthy at birth and have accelerated growth in the 1st year, followed by deceleration and short stature later in childhood.[8] The disease can be diagnosed on the basis of clinical findings like: an enlarged head, short neck, corneal opacity, saddle nose, open mouth associated with macroglossia, widely spaced teeth with relative microdontia, unerupted dentition, dentigerous cyst like follicles, malocclusions, condylar defects, gingival hyperplasia, hepatomegaly and splenomegaly, umbilical and inguinal hernias are common. Growth may be normal for several years and may then stop, resulting in a final stature of 90–140 cm. A short trunk with lumbar lordosis is typically present. Restricted joint movement, including claw-hand deformities, appears in the first few years of life. Examination of the skin frequently reveals hirsutism. Multiple dentigerous cysts can be seen in a few conditions apart from this syndrome, although there have been various reports of multiple dentigerous cysts in literature [Table 2]. Maroteaux–Lamy syndrome is caused by mutations in the ARSB gene. Genes provide instructions for making proteins that play a critical role in many functions of the body. When a mutation of a gene occurs, the protein product may be faulty, inefficient, or absent. Depending on the functions of the particular protein, this can affect many organ systems of the body. Patients with MPS VI require on-going medical care from numerous subspecialists.
Table 1

Review of literature: Different presentations of maroteaux lamy syndrome

Table 2

Reported cases of multiple dentigerous cysts till year 2000

Review of literature: Different presentations of maroteaux lamy syndrome Reported cases of multiple dentigerous cysts till year 2000 In addition, patients should receive routine pediatric care, including immunizations. Obstructive airway disease can result from narrowing of the trachea, enlarged tongue, and redundant tissue. Tracheostomy has been performed in some patients. Tonsillectomy and adenoidectomy are also frequently performed to relieve obstruction. Many patients develop carpal tunnel syndrome, which may require nerve decompression. Enzyme replacement therapy with galsulfase (Naglazyme)[9] has been shown to improve walking and stair-climbing capacity and to decrease urine glycosaminoglycan (GAG) levels in patients with MPS VI. Bone marrow transplantation (BMT) has been attempted in a number of patients with MPS. Although BMT has been of particular interest in treating patients with MPS who are at risk for neurologic disease (MPS IH),[38] BMT has been limited by the associated mortality risk and the need for an appropriately matched donor.

CONCLUSION

Although Maroteaux–Lamy syndrome is not encountered routinely in dental practice, unerupted dentition with dentigerous cyst formation can be rare presentation of the syndrome which if thoroughly investigated can help in diagnosing this rare syndrome with varied clinical features.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  6 in total

1.  Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.

Authors:  Paul Harmatz; Roberto Giugliani; Ida Schwartz; Nathalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; J Edmond Wraith; Michael Beck; Laila Arash; Maurizio Scarpa; Zi-Fan Yu; Janet Wittes; Kenneth I Berger; Mary S Newman; Ann M Lowe; Emil Kakkis; Stuart J Swiedler
Journal:  J Pediatr       Date:  2006-04       Impact factor: 4.406

Review 2.  The oral manifestations of Hurler's syndrome.

Authors:  D G Gardner
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1971-07

3.  The frequency of lysosomal storage diseases in The Netherlands.

Authors:  B J Poorthuis; R A Wevers; W J Kleijer; J E Groener; J G de Jong; S van Weely; K E Niezen-Koning; O P van Diggelen
Journal:  Hum Genet       Date:  1999 Jul-Aug       Impact factor: 4.132

4.  Prevalence of lysosomal storage diseases in Portugal.

Authors:  Rui Pinto; Carla Caseiro; Manuela Lemos; Lurdes Lopes; Augusta Fontes; Helena Ribeiro; Eugénia Pinto; Elisabete Silva; Sónia Rocha; Ana Marcão; Isaura Ribeiro; Lúcia Lacerda; Gil Ribeiro; Olga Amaral; M C Sá Miranda
Journal:  Eur J Hum Genet       Date:  2004-02       Impact factor: 4.246

5.  Occurrence of multiple dentigerous cysts in a patient with the Maroteaux-Lamy syndrome (mucopolysaccharidosis, type VI).

Authors:  M W Roberts; N W Barton; G Constantopoulos; D P Butler; A H Donahue
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1984-08

6.  Prevalence of lysosomal storage disorders.

Authors:  P J Meikle; J J Hopwood; A E Clague; W F Carey
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.